

1 **Supplementary materials inventory**

2

3 The supplementary materials included 3 supplementary Tables and 3 supplementary
4 Figures.

5

6 **Supplementary Table**

7 Table S1: Summary of Clinicopathologic Variables of 72 HCC patients.

8 Table S2: The primer sequences for clone and qPCR.

9 Table S3: Summary of Clinicopathologic Variables of 199 HCC patients in the tissue
10 array.

11

12 **Supplementary Figure**

13 **Figure S1** Down-regulation of PANK1 in the HCC. (A) The screening strategy for
14 PANK1. (B) The expression of PANK1 between normal and primary HCC tumor in
15 TCGA database. (C) Survival analysis of PANK1 in KM Plotter database. (D) The
16 expression of PANK1 in normal tissues in The Human Protein Atlas database.

17 **Figure S2** The correlations between the expression of PANK1 and serum bio-marker
18 of 199 HCC patients in the tissue array. The contents of Alpha fetal protein (AFP) (A),
19 α-L-fucosidase (AFU) (B), Alkaline phosphatase (ALP) (C), Alanine
20 aminotransferase (ALT) (D), Aspartate aminotransferase (AST) (E), Carbohydrate
21 antigen199 (CA199) (F), Carcino-embryonic antigen (CEA) (G), Gamma-glutamyl
22 transpeptidase (GGT) (H), Hepatitis B virus (HBV) DNA (I), Albumin (J),

23 Prothrombin time (PT) (K), Direct Bilirubin (DBIL) (L), and Total bilirubin (TBIL)

24 (M) were measured and the correlations were analyzed.

25 **Figure S3** The interaction between exogenously expressed PANK1 (Flag-PANK1)

26 and RNF43 (A), AXIN1 (B), LRP6 (C), β -catenin (D), DVL2 (E), GSK3 β (F) was

27 examined in 293T cells.

Supplementary Table S1 Summary of Clinicopathologic Variables of 72 HCC patients

Characteristic	No. of Patients
Gender	
Male	60
Female	12
Age (years)	
<55	26
≥55	46
Tumor size (cm)	
<55	31
≥5	41
Tumor number	
≤1	60
≥2	12
HBV infection	
Yes	62
No	10
Organ metastasis	
Yes	7
No	65
Edmondson grading	
I/II	2
II/III	40
III/IV	30
Microvascular invasion (MVI)	
M0	19
M1	35
M2	18


Supplementary Table S2 The primer sequences for clone and qPCR

Gene (homo)	Forward (5'-3')	Reverse (5'-3')
PANK1 (clone)	GGATCCATGTTGAAACTCGTC	GAATTCTACTTGTCA T
shPANK1 1# (clone)	CCGGGCCTGCTTATGTCGAC TCTGCTCGAGCAGAGTCGACA TAAAGCAGGCTTTTG	AATTCAAAAAGCCTGCTTT ATGTCGACTCTGCTCGAGC AGAGTCGACATAAAGCAGG C
shPANK1 2# (clone)	CCGGGCTATGCACAGGT CATT CAGCTCGAGCTGAATGAACCT GTGCATAGCTTTTG	AATTCAAAAAGCTATGCAC AGGTTCATT CAGCTCGAGCT GAATGAACCTGTGCATAGC
PANK1 (qPCR)	CTGCCTTGATAACCCATACCC	CTTGGAGTACACGGCTAGA T ATG
GAPDH (qPCR)	TGTTGCCATCAATGACCCCTT	CTCCACGACGTACTCAGCG
Axin2 (qPCR)	TACACTCCTTATTGGGCGATCA	TTGGCTACTCGTAAAGTTT GGT
18S (qPCR)	AGGCCCTGTAATTGGAAT GAGTC	GCTCCCAAGATCCA ACGAG


Supplementary Table S3 Summary of Clinicopathologic Variables of 199 HCC patients in the tissue array.

Characteristic	No. of Patients
Gender	
male	184
female	15
Age (years)	
≤50	114
>50	85
BMI (kg/m²)	
≤18.5	9
18.5-25	127
≥25	63
Tumor size (cm)	
≤11	170
>11	29
Tumor number	
≤1	174
≥2	25
Paracancerous microtumor	
No	128
Yes	71
Intracancerous hemangioma	
No	116
Yes	83
Ascites	
No	181
Yes	18
Cirrhosis	
I-II	118
III-IV	81
PVTT	
No	174
Yes	25
Capsular invasion	
I-II	140
III	59
Tumor grade	
I-II	50
III	149
Recurrence	
No	57
Yes	142


A




B





















C



D



A**B****C****D****E****F****G****H****I****J****K****L****M**

A**B****C****D****E****F**